Abstract Background/Aims The aim of the MYOSCOPE study was to test the feasibility and impact of using handheld nailfold capillaroscopy (NFC) in clinical practice with children/young people with juvenile dermatomyositis (JDM). Participants and parents’ perspectives are described here. Methods A mixed-methods design, including questionnaires and interviews, was used. JDM patients at two tertiarypaediatric rheumatology centres who were approached to participate in theMYOSCOPE study and their parent/guardian who attended the clinic were eligibleto participate. Age-adjusted questionnaires were given to patients (≥6 years)and parents/carers (for children of all ages) at each clinic visit. Allparticipants were also invited to take part in patient/family interviews. Athematic analysis approach was used to explore the themes within thequalitative data related to views on trial design and acceptability.Quantitative data were analysed using descriptive statistics. Data were thensynthesised using framework analysis to map findings to the adapted theoreticalframework of acceptability. Results Forty patients were recruitedto MYOSCOPE, one patient declined NFC at subsequent visits. Data were collectedfrom 72 participants between October 2024 and September 2025. 112questionnaires were received, linked to all 40 participants (33 patients, 39 parents, across three time points). Twenty-four participants, linked to 16 recruits, also took part in semi-structured interviews (8 patients- 1 decliner, 16parents). There was strong support for the use of NFC during clinic visits.Findings showed that all eight constructs of acceptability were met (affective attitude, burden, ethicality, intervention coherence, opportunity costs, perceived effectiveness, self-efficacy and trust). 110/112 (98.2 %) of questionnaire respondents saidthat they either felt ‘fantastic’, ‘really good’, or ‘okay’about seeing their nailfold capillaries in clinic. Participants felt thatviewing NFC helped increase their general understanding of JDM and the currentcondition of their/their child’s JDM (94/112, 83.9 %). Participants valued thatthe process made an ‘invisible condition visible’ and increased theirunderstanding of why medication was needed 101/112 (90.2 %). 29/38 (76.6%) ofparticipants at second or third visits, felt that seeing NFC helped them/theirchild take their medication more reliably. However, some patients were alreadyon established routines or were in remission/off medication, so adherence wasnot affected. A minority (3/16 recruits represented in the interviews)described experiencing burden in relation to sensory feedback received from theplacement of olive oil on their fingers for NFC. Conclusion Patients and their parents found the use of NFC in JDM clinics acceptable and desirable, increasing understanding of JDM and reinforcing the need to take medication as prescribed. If using NFC in clinical situations, accommodations need to be in place to prevent negative sensory feedback. Disclosure E. Deja: None. K. Roberts: None. L. Huckerby: None. C. Papadopoulou: None. A. Murray: None. G. Dinsdale: None. M. Hadjittofi: None. J.S. Ainsworth: None. A. Vail: None. K. Kupiec: None. Y. Glakin: None. J. Fitzgerald: None. L. Wedderburn: None. C. Pain: None. C. Taylor: None. A. Herrick: None. L. McCann: None.
Deja et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: